EAM
ALDR

Eventide Asset Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Eventide Asset Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-79,000
Closed -$1.64M – 134
2017
Q1 		$1.64M Sell
79,000
-136,000
-63% -$3.01M 0.11% 95
2016
Q4 		$4.47M Buy
+215,000
New +$5.59M 0.29% 73

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Eventide Asset Management's ALDR Position: Q2 2017 in Review

Eventide Asset Management sold out of Alder Biopharmaceuticals (ALDR) in Q2 2017, closing a stake of 79,000 shares — an estimated $1.64M sold.

Eventide Asset Management first reported a position in ALDR in Q4 2016 and held it in 2 quarters. The position peaked at $4.47M in Q4 2016. 128 funds tracked by Wall St. Rank hold ALDR as of Q2 2017.

  • Eventide Asset Management reported no remaining Alder Biopharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Eventide Asset Management sold 79,000 Alder Biopharmaceuticals shares in Q2 2017, an estimated $1.64M.
  • Eventide Asset Management first reported a position in Alder Biopharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Eventide Asset Management's Alder Biopharmaceuticals position peaked at $4.47M in Q4 2016.
  • 128 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q2 2017.

Based on Eventide Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.